The efficacy and safety of oral immediate-release oxymorphone for postsurgical pain

Anesthesia and Analgesia

Volumn 99, Issue 5, 2004, Pages 1472-1477

  Gimbel, Joseph ^a   Ahdieh, Harry ^b  

^a Arizona Research Center   (United States)

^b ENDO PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OXYCODONE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMA; CONSCIOUSNESS DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; FEMALE; HUMAN; HYPOTENSION; ILEUS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPIOID INDUCED EMESIS; PAIN ASSESSMENT; POSTOPERATIVE ANALGESIA; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; SIDE EFFECT; SOMNOLENCE; SWEATING;

ADOLESCENT; ADULT; AGED; ANALGESICS, OPIOID; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MENTAL RECALL; MIDDLE AGED; OXYCODONE; OXYMORPHONE; PAIN MEASUREMENT; PAIN, POSTOPERATIVE; POSTOPERATIVE NAUSEA AND VOMITING;

EID: 6444221477     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ANE.0000132548.91622.B3     Document Type: Article

References (14)

1. Sinatra RS, Torres J, Bustos AM. Pain management after major orthopaedic surgery: current strategies and new concepts. J Am Acad Orthop Surg 2002;10:117-29.
2. American Society of Anesthesiologists. A report by the American Society of Anesthesiologists Task Force on Pain Management, Acute Pain Section. Anesthesiology 1995;82:1071-81.
3. Sinatra RS, Hyde NH, Harrison DM. Oxymorphone revisited. Semin Anesth 1988;7:209-15.
4. Beaver WT, Feise GA. A comparison of the analgesic effect of oxymorphone by rectal suppository and intramuscular injection in patients with postoperative pain. J Clin Pharmacol 1977;17:276-91.
5. Eddy NB, Lee LEJ. The analgesic equivalence to morphine and relative side action liability of oxymorphone (4-hydroxydihydromorphinone). J Pharmacol Exp Ther 1959;125:116-21.
6. Metzger TG, Paterlini MG, Ferguson DM, Portoghese PS. Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus. J Med Chem 2001;44:857-62.
7. Mather LE. Pharmacokinetics and patient-controlled analgesia. Acta Anaesthesiol Belg 1992;43:5-20.
8. International Conference on Harmonization. Medical Dictionary for Regulatory Activities (MedDRA). Reston, VA: Northrup Grumman, 2003.
9. Thirlwell MP, Sloan PA, Maroun JA, et al. Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients. Cancer 1989;63:2275-83.
10. Leow KP, Smith MT, Williams B, Cramond T. Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Clin Pharmacol Ther 1992;52:487-95.
11. Gabrail NY, Dvergsten C, Ahdieh H. Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study. Curr Med Res Opin 2004;20:911-8.
12. Wilkins KL, McGrath PJ, Finley GA, Katz J. Phantom limb sensations and phantom limb pain in child and adolescent amputees. Pain 1998;78:7-12.
13. Arnstein PM. The neuroplastic phenomenon: a physiologic link between chronic pain and learning. J Neurosci Nurs 1997;29:179-86.
14. Coderre TJ, Katz J, Vaccarino AL, Melzack R. Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain 1993;52:259-85.